Full Enrollment Reached in Pivotal Phase III Pancreatic Cancer Trial, Data Readout Set for H2 2027
RNXT sits 61% above its 52-week low of $0.701.
Summary
RenovoRx has fully enrolled its Phase III TIGeR-PaC trial in locally advanced pancreatic cancer, a critical step toward validating its TAMP therapy platform. With 78 of the required 86 events already observed, trial completion is expected in H1 2027 and topline data in H2 2027. This follows a series of positive developments, including promising pharmacokinetic data and FDA Orphan Drug Designation for oxaliplatin. The milestone de-risks the clinical timeline and brings the company closer to a potential regulatory filing, though the ultimate outcome hinges on the survival data. The stock, trading near $1.13 with a $52M market cap, faces a Nasdaq compliance deadline in December 2026, adding urgency to the data readout.
At the time of this announcement, RNXT was trading at $1.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $52.3M. The 52-week trading range was $0.70 to $1.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.